tbuckley/cabot-search huggingface dataset:
Issue Information
Authors: Daniel Solomon, Richard Bucala, New Haven, Mariana Kaplan, Peter Nigrovic, Boston Co, Karen Costenbader, David Felson, Richard Loeser, Chapel Hill, Paul Sufka, St Paul, Amr Sawalha, Susan Boackle, Aileen Davis, Daniel Horton, New Brunswick, Bharat Kumar, Iowa City, Brandon Law, Michelle Ormseth, Suraj Rajasimhan, Kimberly Murphy, Lesley Allen, Virginia Ilani, S Lorber, Stefanie Mckain, Georgia Rasa, G Hamilton, Brian Robinson, Christopher Reynolds, Georgia Jenson, Marta Alarcón-Riquelme, Heather Allore, Neal Basu, Edward Behrens, Bryce Binstadt, Nunzio Bottini, San Diego, John Carrino, New York, Andrew Cope, Adam Croft, Nicola Dalbeth, Brian Feldman, Richard Furie, Great Neck, J Kahlenberg, Ann Arbor, Benjamin Leder, Yvonne Lee, Katherine Liao, Bing Lu, Stephen Messier, Winston-Salem Rachel, E Miller, Janet Pope, Lisa Rider, Christopher Ritchlin, Rochester Robinson, Carla Scanzello, Georg Schett, Sakae Tanaka, Maria Trojanowska, Betty Tsao, Fredrick Wigley, Edith Williams, Ayaz Aghayev, Joshua Baker, Bonnie Bermas, Jamie Collins, Kristen Demoruelle, Denver Denton, Anisha Dua, John Fitzgerald, Angeles Henderson, Monique Hinchcliff, Hui-Chen Hsu, Mohit Kapoor, Seoyoung Kim, Vasileios Kyttaris, Carl Langefeld, Winston-Salem Dennis Mcgonagle, Julie Paik, Julie Zikherman, Francisco American, Douglas White, La Crosse, Deborah Desir, Carol Langford, Steven Echard, Ruth Fernandez-Ruiz, Alí Duarte-García, Noelle Rolle, Sebastian Sattui, Didem Saygin, Sharon Dowell, Akilan Krishnamurthy, Alexandra Circiumaru, Jitong Sun, Yogan Kisten, Peter Damberg, Koji Sakuraba, Katalin Sandor, Patrik Jarvoll, Jin Park, Yun Lee, Kichul Shin, Eun Kang, You-Jung Ha, Jun Park, Min Kim, Mi Kim, Marc Maurits, Fenne Wouters, Ellis Niemantsverdriet, Thomas Huizinga, Ernst Shanahan, Lucinda Robinson, Suellen Lyne, Richard Woodman, Fin Cai, Judith Rademacher, Hanna Müllner, Torsten Diekhoff, Hildrun Haibel, Sabrina Igel, Dominika Pohlmann, Fabian Proft, Mikhail Protopopov, Tri Tran, Tejpal Gill, Joshua Bennett, Vance Hong, Anders Holt, Keith Bakshi, Joel Sikora, Rouhin Sen, Emmeline Kim, Ruth Napier, Elizabeth Cheng, Andrea Fernandez, Evan Manning, Eric Anderson, Kyle Maier, Mena Hashim, Gail Kerr, Meika Fang, Jason Hou
Journal: Arthritis & Rheumatology (2023)
A deep learning method for classification of steady-state visual evoked potentials in a brain-computer interface speller
Authors: Farzad Saffari, Ali Khadem
Journal: Brain-Computer Interfaces (2023)

The main drawback of SSVEP-based BCIs is the lack of a classifier that categorizes SSVEPs with high accuracy and Information Transfer Rate (ITR). Addressing this, we proposed a deep convolutional neural network (CNN) for classifying a 40-class SSVEP. Time windows of length 2 and 3.5 seconds were used for training and testing the model by leave-one-subject-out cross-validation, using nine, three, and single-channel EEG. The proposed model reached 88.5% average accuracy for the nine-channel EEG with the mean and max ITR of 72 and 91.23 bpm, respectively. It outperformed the previous deep learning methods for SSVEP-based BCIs, in terms of accuracy and ITR. In the three-channel experiment the mean accuracy and ITR were 76.02% and 40.1 bpm. In single-channel implementation, O1 channel achieved 77.38 % average accuracy (highest) and the mean ITR was 57.51 bpm. The model showed promising performance to put this technology forward and make it more practical.
Water-responsive gel extends drug retention and facilitates skin penetration for curcumin topical delivery against psoriasis
Authors: Qing Yao, Yuanyuan Zhai, Zhimin He, Qian Wang, Lining Sun, Tuyue Sun, Leyao Lv, Yingtao Li, Jiyong Yang, Donghui Lv, Ruijie Chen, Hailin Zhang, Xiang Luo, Longfa Kou
Journal: Asian Journal of Pharmaceutical Sciences (2023)

Psoriasis is a chronic inflammatory skin disease characterized by erythema, scaling, and skin thickening. Topical drug application is recommended as the first-line treatment. Many formulation strategies have been developed and explored for enhanced topical psoriasis treatment. However, these preparations usually have low viscosity and limited retention on the skin surface, resulting in low drug delivery efficiency and poor patient satisfaction. In this study, we developed the first water-responsive gel (WRG), which has a distinct water-triggered liquid-to-gel phase transition property. Specifically, WRG was kept in a solution state in the absence of water, and the addition of water induced an immediate phase transition and resulted in a high viscosity gel. Curcumin was used as a model drug to investigate the potential of WRG in topical drug delivery against psoriasis. In vitro and in vivo data showed that WRG formulation could not only extend skin retention but also facilitate the drug permeating across the skin. In a mouse model of psoriasis, curcumin loaded WRG (CUR-WRG) effectively ameliorated the symptoms of psoriasis and exerted a potent anti-psoriasis effect by extending drug retention and facilitating drug penetration. Further mechanism study demonstrated that the anti-hyperplasia, anti-inflammation, anti-angiogenesis, anti-oxidation, and immunomodulation properties of curcumin were amplified by enhanced topical drug delivery efficiency. Notably, neglectable local or systemic toxicity was observed for CUR-WRG application. This study suggests that WRG is a promising formulation for topically psoriasis treatment.
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Authors: Paula Rodriguez-Otero, Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie Callander, Luciano J. Costa, Ravi Vij, Nizar J. Bahlis, Philippe Moreau, Scott R. Solomon, Michel Delforge, Jesus Berdeja, Anna Truppel-Hartmann, Zhihong Yang, Linda Favre-Kontula, Fan Wu, Julia Piasecki, Mark Cook, Sergio Giralt
Journal: New England Journal of Medicine (2023)

Survival is poor among patients with triple-class–exposed relapsed and refractory multiple myeloma. Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy, previously led to deep, durable responses in patients with heavily pretreated relapsed and refractory multiple myeloma. Download a PDF of the Research Summary. In this international, open-label, phase 3 trial involving adults with relapsed and refractory multiple myeloma who had received two to four regimens previously (including immunomodulatory agents, proteasome inhibitors, and daratumumab) and who had disease refractory to the last regimen, we randomly assigned patients in a 2:1 ratio to receive either ide-cel (dose range, 150×106 to 450×106 CAR-positive T cells) or one of five standard regimens. The primary end point was progression-free survival. Key secondary end points were overall response (partial response or better) and overall survival. Safety was assessed. A total of 386 patients underwent randomization: 254 to ide-cel and 132 to a standard regimen. A total of 66% of the patients had triple-class–refractory disease, and 95% had daratumumab-refractory disease. At a median follow-up of 18.6 months, the median progression-free survival was 13.3 months in the ide-cel group, as compared with 4.4 months in the standard-regimen group (hazard ratio for disease progression or death, 0.49; 95% confidence interval, 0.38 to 0.65; P<0.001). A response occurred in 71% of the patients in the ide-cel group and in 42% of those in the standard-regimen group (P<0.001); a complete response occurred in 39% and 5%, respectively. Data on overall survival were immature. Adverse events of grade 3 or 4 occurred in 93% of the patients in the ide-cel group and in 75% of those in the standard-regimen group. Among the 225 patients who received ide-cel, cytokine release syndrome occurred in 88%, with 5% having an event of grade 3 or higher, and investigator-identified neurotoxic effects occurred in 15%, with 3% having an event of grade 3 or higher. Ide-cel therapy significantly prolonged progression-free survival and improved response as compared with standard regimens in patients with triple-class–exposed relapsed and refractory multiple myeloma who had received two to four regimens previously. The toxicity of ide-cel was consistent with previous reports. (Funded by 2seventy bio and Celgene, a Bristol-Myers Squibb company; KarMMa-3 ClinicalTrials.gov number, NCT03651128.) QUICK TAKE VIDEO SUMMARYIde-cel in Relapsed and Refractory Multiple Myeloma 02:00
Defining rurality: an evaluation of rural definitions and the impact on survival estimates
Authors: Jeffrey A Franks, Elizabeth S Davis, Smita Bhatia, Kelly M Kenzik
Journal: JNCI Journal of the National Cancer Institute (2023)

Abstract Background Patients with cancer living in rural areas have inferior cancer outcomes; however, studies examining this association use varying definitions of “rural,” complicating comparisons and limiting the utility of the results for policy makers and future researchers. Methods Surveillance, Epidemiology, and End Results data (2000-2016) were used to assess risk of cancer mortality and mortality from any cause across 4 definitions of rurality: Urban Influence codes (UIC), National Center for Health Statistics (NCHS), Rural-Urban continuum codes (RUCC), and Index of Relative Rurality. Binary (urban vs rural) and ternary (urban, micropolitan, rural) definitions were evaluated. Multivariable parametric survival models estimated hazards of mortality overall and among 3 cancer groupings: screening related, obesity related, and tobacco related. Definition agreement was also assessed. Results Overall, 3 788 273 patients with an incident cancer representing 605 counties were identified. There was little discordance between binary definitions of rural vs urban and moderate agreement at the 3 levels. Adjusted models using binary definitions revealed 15% to 17% greater hazard of cancer mortality in rural compared with urban. At the 3 levels when comparing rural with metropolitan, RUCC and NCHS saw similarly increased hazard ratios; however, Index of Relative Rurality did not. Screening-related cancers saw the highest hazards of mortality and the largest divergence between definitions. Obesity-related and tobacco-related cancers saw similarly increased hazards of mortality at the binary and ternary levels. Conclusions Hazard of death is similar across binary definitions; however, this differed when categorized as ternary or continuous, especially among screening-related cancers. Results suggest that study purpose should direct choice of definitions and categorization.
Promotion of Joint Degeneration and Chondrocyte Metabolic Dysfunction by Excessive Growth Hormone in Mice
Authors: Shouan Zhu, Huanhuan Liu, Trent Davis, Craig R. G. Willis, Reetobrata Basu, Luke Witzigreuter, Stephen Bell, Nathaniel Szewczyk, Martin K. Lotz, Marcheta Hill, Roberto J. Fajardo, Patrick M. O'Connor, Darlene E. Berryman, John J. Kopchick
Journal: Arthritis & Rheumatology (2023)

Many patients with acromegaly, a hormonal disorder with excessive growth hormone (GH) production, report pain in joints. We undertook this study to characterize the joint pathology of mice with overexpression of bovine GH (bGH) or a GH receptor antagonist (GHa) and to investigate the effect of GH on regulation of chondrocyte cellular metabolism.
Implementation of a Multimodal Knowledge-Exchange Platform to Provide Trauma Critical Care Education During the Ongoing Conflict in Ukraine
Authors: Lucrezia Rovati, Simon Zec, Dmytro Dziuba, Anna Masoodi, Aysun Tekin, Claudia Castillo Zambrano, Meghan Brown, Oleksiy Khavryuchenko, Oleksandr Bugay, Grygorii Khytryi, Oleg Loskutov, Yue Dong, Ognjen Gajic, Alexander S. Niven
Journal: JAMA Network Open (2023)

Importance The conflict in Ukraine has forced civilian hospitals with limited trauma and battlefield medicine experience to care for casualties of war, placing significant strain on the health care system. Using the Checklist for Early Recognition and Treatment of Acute Illness and Injury (CERTAIN) program, a multimodal trauma critical care knowledge-exchange platform was created for clinicians practicing in these institutions. Objectives To describe the development and implementation of the CERTAIN for Ukraine program and to evaluate the reach of this intervention, together with participant engagement and satisfaction. Design, Setting, and Participants This quality improvement study included clinicians caring for critically ill patients during the ongoing Ukrainian conflict who were part of a community developed using a messaging app. The program was implemented by a group of international trauma and critical care experts in collaboration with critical care leaders from the Shupyk National Healthcare University in Kyiv, Ukraine. This study evaluates data collected from the CERTAIN for Ukraine program from its launch on April 9, 2022, to August 31, 2022. Interventions The initiative comprised a longitudinal series of interactive tele-education sessions, a webpage containing the CERTAIN approach and current trauma critical care guidelines translated into Ukrainian and Russian, and a private messaging chat for asynchronous discussion. Main Outcomes and Measures Participant engagement and satisfaction were tracked using multimedia analytics and a post-session survey. Results Since program launch, 838 participants have joined the messaging group, and 6 tele-education sessions have been delivered, with 1835 total views. The CERTAIN website has had 3527 visits, mainly from Ukraine (1378 [39%]) and the United States (1060 [30%]). Of the 74 completed postsession surveys, 65 respondents (88%) rated the course content excellent or very good, and 73 (99%) recommended it to others. Conclusions and Relevance The findings of this quality improvement study indicate that, using widely available and low-cost platforms, knowledge was shared rapidly and efficiently to a large community of clinicians practicing in a wartime environment with broad-based engagement and a high level of learner satisfaction.
Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial
Authors: Hatem Soliman, Deanna Hogue, Hyo Han, Blaise Mooney, Ricardo Costa, Marie C. Lee, Bethany Niell, Angela Williams, Alec Chau, Shannon Falcon, Aixa Soyano, Avan Armaghani, Nazanin Khakpour, Robert J. Weinfurtner, Susan Hoover, John Kiluk, Christine Laronga, Marilin Rosa, Hung Khong, Brian Czerniecki
Journal: Nature Medicine (2023)
Genitourinary Syndrome of Menopause and the False Promise of Vaginal Laser Therapy
Authors: Jen Gunter
Journal: JAMA Network Open (2023)

Eduard Mension, MD, MSc; Inmaculada Alonso, MD, PhD; Sònia Anglès-Acedo, MD, PhD; Cristina Ros, MD, PhD; Jorge Otero, PhD; Álvaro Villarino, MSc; Ramon Farré, PhD; Adela Saco, MD, PhD; Naiara Vega, BSC; Natalia Castrejón, MD; Jaume Ordi, MD, PhD; Natalia Rakislova, MD, PhD; Marta Tortajada, MD; Isabel Matas, MD; Sílvia Gómez, MD; Laura Ribera, MD; Camil Castelo-Branco, MD, PhD
Trends in In-Hospital Cardiac Arrest and Mortality Among Children With Cardiac Disease in the Intensive Care Unit
Authors: Francesca Sperotto, Marco Daverio, Angela Amigoni, Dario Gregori, Anna Dorste, Catherine Allan, Ravi R. Thiagarajan
Journal: JAMA Network Open (2023)

Importance Data on trends in incidence and mortality for in-hospital cardiac arrest (IHCA) in children with cardiac disease in the intensive care unit (ICU) are lacking. Additionally, there is limited information on factors associated with IHCA and mortality in this population. Objective To investigate incidence, trends, and factors associated with IHCA and mortality in children with cardiac disease in the ICU. Data Sources A systematic review was conducted using PubMed, Web of Science, EMBASE, and CINAHL, from inception to September 2021. Study Selection Observational studies on IHCA in pediatric ICU patients with cardiac disease were selected (age cutoffs in studies varied from age ≤18 y to age ≤21 y). Data Extraction and Synthesis Quality of studies was assessed using the National Institutes of Health Quality Assessment Tools. Data on incidence, mortality, and factors associated with IHCA or mortality were extracted by 2 independent observers. Random-effects meta-analysis was used to compute pooled proportions and pooled ORs. Metaregression, adjusted for type of study and diagnostic category, was used to evaluate trends in incidence and mortality. Main Outcomes and Measures Primary outcomes were incidence of IHCA and in-hospital mortality. Secondary outcomes were proportions of patients who underwent extracorporeal membrane oxygenation (ECMO) cardiopulmonary resuscitation (ECPR) and those who did not achieve return of spontaneous circulation (ROSC). Results Of the 2574 studies identified, 25 were included in the systematic review (131 724 patients) and 18 in the meta-analysis. Five percent (95% CI, 4%-6%) of children with cardiac disease in the ICU experienced IHCA. The pooled in-hospital mortality among children who experienced IHCA was 51% (95% CI, 42%-59%). Thirty-nine percent (95% CI, 29%-51%) did not achieve ROSC; in centers with ECMO, 22% (95% CI, 14%-33%) underwent ECPR, whereas 22% (95% CI, 12%-38%) were unable to be resuscitated. Both incidence of IHCA and associated in-hospital mortality decreased significantly in the last 20 years (both P for trend &amp;amp;lt; .001), whereas the proportion of patients not achieving ROSC did not significantly change ( P for trend = .90). Neonatal age, prematurity, comorbidities, univentricular physiology, arrhythmias, prearrest mechanical ventilation or ECMO, and higher surgical complexity were associated with increased incidence of IHCA and mortality odds. Conclusions and Relevance This systematic review and meta-analysis found that 5% of children with cardiac disease in the ICU experienced IHCA. Decreasing trends in IHCA incidence and mortality suggest that education on preventive interventions, use of ECMO, and post-arrest care may have been effective; however, there remains a crucial need for developing resuscitation strategies specific to children with cardiac disease.
Trends in Out-of-Pocket Costs for and Characteristics of Pharmacy-Dispensed Buprenorphine Medications for Opioid Use Disorder Treatment by Type of Payer, 2015 to 2020
Authors: Andrea E. Strahan, Shaina Desai, Kun Zhang, Gery P. Guy
Journal: JAMA Network Open (2023)

Importance Buprenorphine has been approved for opioid use disorder treatment, yet remains underutilized. Cost may present a barrier; little is known about how out-of-pocket costs vary. Objective To determine if out-of-pocket costs and prescription characteristics for buprenorphine varied by type of payer. Design, Setting, and Participants This cross-sectional study used all-payer data on retail pharmacy–dispensed buprenorphine prescriptions from January 1, 2015, through December 31, 2020, for adults (aged ≥18 years) in the US, excluding formulations primarily used to treat pain. Data were analyzed from July 2021 to June 2022. Exposures Type of payer (private and commercial, self-pay, Medicaid, Medicare, assistance, and unknown) for dispensed prescription. Main Outcomes and Measures All outcomes are prescription-level. Mean and median daily out-of-pocket costs were calculated overall and by payer type. Prescription characteristics (days supplied, patient age and sex, generic vs name brand formulations, and prescriber’s location) were examined by payer type. Results Although mean daily out-of-pocket costs decreased overall from $4.79 (95% CI, $4.79-$4.80) in 2015 (7 375 508 prescriptions) to $1.91 (95% CI, $1.90-$1.91) in 2020 (13 486 822 prescriptions), out-of-pocket costs continued to vary by payer in 2020. Medicaid had the lowest mean daily out-of-pocket cost across all years—$0.18 (95% CI, $0.18-$0.18) in 2015, and $0.10 (95% CI, $0.10-$0.10) in 2020. Private and commercial paid prescriptions fell from $4.80 (95% CI, $4.79-$4.81) per day in 2015 to $1.82 (95% CI, $1.82-$1.83) in 2020. Self-pay and assistance categories had the highest mean daily out-of-pocket costs across study years ($9.76 [95% CI, $9.74-$9.78] and $8.72 [95% CI, $8.71-$8.73], respectively, in 2015; $8.44 [95% CI, $8.43-$8.46] and $6.31 [95% CI, $6.30-$6.31], respectively, in 2020). Medicaid paid prescriptions had a mean supply of 15.59 days (95% CI, 15.58-15.59 days) and the lowest percentage of generic prescriptions (57.88%; 95% CI, 57.84%-57.92%). Out-of-pocket cost varied by prescriber location and patient characteristics; mean costs were highest for prescriptions written in the South ($2.91; 95% CI, $2.90-$2.91), metropolitan counties ($1.93; 95% CI, $1.93-$1.93), and for individuals aged 35 to 44 years ($2.10; 95% CI, $2.09-$2.10). Conclusions and Relevance This cross-sectional study found that mean daily out-of-pocket costs for buprenorphine were lower in 2020 than in 2015, but variation by payer existed in all study years. Financial barriers to accessing and maintaining buprenorphine for opioid use disorder treatment may exist and differ by type of prescription coverage. Future research could monitor costs and identify potential barriers that may impact access and retention in care.
Conventional therapy in psoriasis. Lost in translation?
Authors: Jose-Manuel Carrascosa
Journal: British Journal of Dermatology (2023)

As no more than one out of every 3 patients receiving a first course of acitretin, cyclosporin or fumaric acid esters achieved contemporary therapeutic objectives in psoriasis, biosimilars could be positioned as the first line of treatment in patients with moderate to severe psoriasis.